FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153602227> ?p ?o ?g. }

• W2153602227 abstract "Chemotherapy resistance associated with recurrent disease is the major cause of poor survival of ovarian cancer patients. We have recently demonstrated activation of the JAK2/STAT3 pathway and the enhancement of a cancer stem cell (CSC)-like phenotype in ovarian cancer cells treated in vitro with chemotherapeutic agents. To elucidate further these mechanisms in vivo, we used a two-tiered paclitaxel treatment approach in nude mice inoculated with ovarian cancer cells. In the first approach, we demonstrate that a single intraperitoneal administration of paclitaxel in mice 7 days after subcutaneous transplantation of the HEY ovarian cancer cell line resulted in a significant increase in the expression of CA125, Oct4, and CD117 in mice xenografts compared to control mice xenografts which did not receive paclitaxel. In the second approach, mice were administered once weekly with paclitaxel and/or a daily dose of the JAK2-specific inhibitor, CYT387, over 4 weeks. Mice receiving paclitaxel only demonstrated a significant decrease in tumor volume compared to control mice. At the molecular level, mouse tumors remaining after paclitaxel administration showed a significant increase in the expression of Oct4 and CD117 coinciding with a significant activation of the JAK2/STAT3 pathway compared to control tumors. The addition of CYT387 with paclitaxel resulted in the suppression of JAK2/STAT3 activation and abrogation of Oct4 and CD117 expression in mouse xenografts. This coincided with significantly smaller tumors in mice administered CYT387 in addition to paclitaxel, compared to the control group and the group of mice receiving paclitaxel only. These data suggest that the systemic administration of paclitaxel enhances Oct4- and CD117-associated CSC-like marker expression in surviving cancer cells in vivo, which can be suppressed by the addition of the JAK2-specific inhibitor CYT387, leading to a significantly smaller tumor burden. These novel findings have the potential for the development of CSC-targeted therapy to improve the treatment outcomes of ovarian cancer patients." @default.
• W2153602227 created "2016-06-24" @default.
• W2153602227 creator A5003231470 @default.
• W2153602227 creator A5029344208 @default.
• W2153602227 creator A5035820439 @default.
• W2153602227 creator A5044583406 @default.
• W2153602227 creator A5085704487 @default.
• W2153602227 creator A5088204119 @default.
• W2153602227 creator A5089788519 @default.
• W2153602227 creator A5090327179 @default.
• W2153602227 date "2014-04-09" @default.
• W2153602227 modified "2023-10-16" @default.
• W2153602227 title "Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden" @default.
• W2153602227 cites W1554638747 @default.
• W2153602227 cites W1892496998 @default.
• W2153602227 cites W1968002492 @default.
• W2153602227 cites W1970851801 @default.
• W2153602227 cites W1981957956 @default.
• W2153602227 cites W1988622416 @default.
• W2153602227 cites W2000707284 @default.
• W2153602227 cites W2007501395 @default.
• W2153602227 cites W2009337734 @default.
• W2153602227 cites W2010293026 @default.
• W2153602227 cites W2010435558 @default.
• W2153602227 cites W2011176465 @default.
• W2153602227 cites W2012582486 @default.
• W2153602227 cites W2019865561 @default.
• W2153602227 cites W2023587718 @default.
• W2153602227 cites W2024460791 @default.
• W2153602227 cites W2048113014 @default.
• W2153602227 cites W2049306821 @default.
• W2153602227 cites W2052152283 @default.
• W2153602227 cites W2053271495 @default.
• W2153602227 cites W2055498399 @default.
• W2153602227 cites W2061434125 @default.
• W2153602227 cites W2062165914 @default.
• W2153602227 cites W2067067209 @default.
• W2153602227 cites W2073851843 @default.
• W2153602227 cites W2074702359 @default.
• W2153602227 cites W2075131681 @default.
• W2153602227 cites W2077255241 @default.
• W2153602227 cites W2085595605 @default.
• W2153602227 cites W2089818916 @default.
• W2153602227 cites W2094829108 @default.
• W2153602227 cites W2107319030 @default.
• W2153602227 cites W2109704586 @default.
• W2153602227 cites W2116401711 @default.
• W2153602227 cites W2125933228 @default.
• W2153602227 cites W2128945160 @default.
• W2153602227 cites W2129644533 @default.
• W2153602227 cites W2132195064 @default.
• W2153602227 cites W2133611176 @default.
• W2153602227 cites W2150628057 @default.
• W2153602227 cites W2169850671 @default.
• W2153602227 cites W2170556339 @default.
• W2153602227 cites W4233798790 @default.
• W2153602227 doi "https://doi.org/10.3389/fonc.2014.00075" @default.
• W2153602227 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3988380" @default.
• W2153602227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24782986" @default.
• W2153602227 hasPublicationYear "2014" @default.
• W2153602227 type Work @default.
• W2153602227 sameAs 2153602227 @default.
• W2153602227 citedByCount "61" @default.
• W2153602227 countsByYear W21536022272014 @default.
• W2153602227 countsByYear W21536022272015 @default.
• W2153602227 countsByYear W21536022272016 @default.
• W2153602227 countsByYear W21536022272017 @default.
• W2153602227 countsByYear W21536022272018 @default.
• W2153602227 countsByYear W21536022272019 @default.
• W2153602227 countsByYear W21536022272020 @default.
• W2153602227 countsByYear W21536022272021 @default.
• W2153602227 countsByYear W21536022272022 @default.
• W2153602227 countsByYear W21536022272023 @default.
• W2153602227 crossrefType "journal-article" @default.
• W2153602227 hasAuthorship W2153602227A5003231470 @default.
• W2153602227 hasAuthorship W2153602227A5029344208 @default.
• W2153602227 hasAuthorship W2153602227A5035820439 @default.
• W2153602227 hasAuthorship W2153602227A5044583406 @default.
• W2153602227 hasAuthorship W2153602227A5085704487 @default.
• W2153602227 hasAuthorship W2153602227A5088204119 @default.
• W2153602227 hasAuthorship W2153602227A5089788519 @default.
• W2153602227 hasAuthorship W2153602227A5090327179 @default.
• W2153602227 hasBestOaLocation W21536022271 @default.
• W2153602227 hasConcept C121608353 @default.
• W2153602227 hasConcept C126322002 @default.
• W2153602227 hasConcept C150903083 @default.
• W2153602227 hasConcept C203014093 @default.
• W2153602227 hasConcept C207001950 @default.
• W2153602227 hasConcept C2776694085 @default.
• W2153602227 hasConcept C2777292972 @default.
• W2153602227 hasConcept C2780427987 @default.
• W2153602227 hasConcept C502942594 @default.
• W2153602227 hasConcept C71924100 @default.
• W2153602227 hasConcept C86803240 @default.
• W2153602227 hasConcept C98274493 @default.
• W2153602227 hasConceptScore W2153602227C121608353 @default.
• W2153602227 hasConceptScore W2153602227C126322002 @default.
• W2153602227 hasConceptScore W2153602227C150903083 @default.
• W2153602227 hasConceptScore W2153602227C203014093 @default.
• W2153602227 hasConceptScore W2153602227C207001950 @default.

• next